A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma
NCT ID: NCT00783289
Last Updated: 2019-12-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
35 participants
INTERVENTIONAL
2008-11-14
2009-11-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.
Placebo
Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.
Benralizumab 25 mg
Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
Benralizumab 25 mg
Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
Benralizumab 100 mg
Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
Benralizumab 100 mg
Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
Benralizumab 200 mg
Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.
Benralizumab 200 mg
Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.
Benralizumab 25 mg
Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
Benralizumab 100 mg
Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
Benralizumab 200 mg
Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 through 80 years at screening
* Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
* Previously documented diagnosis of asthma of more than or equal to (\>=) 1 year duration, based on episodic symptoms of airflow obstruction; post-bronchodilator reversibility of airflow obstruction \>=12 percent (%) (at screening or documented within 1 year prior to randomization); or proof of a positive response to a methacholine challenge (documented within 1 year prior to randomization) as represented by a provoking concentration of methacholine to cause a 20% fall in forced expiratory volume in 1 second (FEV1); (PC20) less than (\<) 8 milligram per milliliter (mg/mL)
* Weight of \>=45 kilogram (kg) but less than or equal to (\<=) 135 kg (\>=100 pounds \[lb\] but \<=300 lb)
* Able to produce spirometry readings that meet American Thoracic Society (ATS)/European Respiratory Society (ERS) standards
* Screening pre-bronchodilator FEV1 \>=60%
* Women of childbearing potential, unless surgically sterile (including tubal ligation) and/or at least 2 years post-menopausal, must use 2 effective methods of avoiding pregnancy (including oral, transdermal, or implanted contraceptives, intrauterine device, female condom with spermicide, diaphragm with spermicide, cervical cap, abstinence, use of a condom with spermicide by the sexual partner, or sterile sexual partner) for 14 days prior to the first dose of the investigational product on Study Day 0, and must agree to continue using such precautions through Study Day 161. Cessation of birth control after this point should be discussed with a responsible physician
* Men, unless surgically sterile, must likewise use 2 effective methods of birth control (for example, condom with spermicide) and must agree to continue using such contraceptive precautions through End of Study/Study Day 161
* Ability to complete the study period, including follow-up period until Study Day 161 as required by protocol
Exclusion Criteria
* History of allergy or reaction to any component of the investigational product formulation
* History of allergy or reaction to any other marketed or experimental monoclonal antibody therapies, intravenous gammaglobulin (IVIG), or blood products
* Receipt of any investigational drug therapy within 30 days prior to randomization into the study or any biologic(s) within 5 half-lives of the agent prior to randomization into the study
* Treatment with an oral or systemic burst of corticosteroids within 4 weeks prior to randomization into the study
* Use of any chronic systemic immunosuppressive drugs, including oral corticosteroids within 4 weeks prior to randomization into the study
* Current use of any oral or ophthalmic beta-adrenergic antagonist (for example, propranolol), must have been stopped 2 weeks prior to randomization into the study
* Current allergy vaccination (immunotherapy)
* History of anaphylaxis
* Lung disease other than persistent asthma (for example, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease \[COPD\], tuberculosis \[TB\])
* Acute illnesses or evidence of significant active infection, such as fever \>=38.0 degrees Celsius \[C\] (\>=100.5 degrees Fahrenheit \[F\]) at screening and up through time of the first dose of the investigational product
* History of ingestion of untreated water in a location known to be infected with parasites, resulting in acute or chronic diarrhea; or an untreated parasitic infection within 1 month of randomization
* Pregnancy (women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to administration of the investigational product)
* Lactating woman
* Infection with human immunodeficiency virus (HIV)-1, HIV-2, or hepatitis A, B, or C virus
* History of cancer, apart from basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy \>= 1 year prior to randomization into the study
* History of cigarette smoking \>=10 pack years
* History of alcohol abuse or drug abuse that required treatment \<1 year prior to randomization into the study
* Elective surgery planned during the study period
* Evidence of any systemic disease or any finding upon physical examination, laboratory abnormality, chest x-ray (CXR), or electrocardiogram (ECG) that, in the opinion of the investigator or medical monitor, may compromise the safety of the subject in the study or confound the analysis of the study results
* Employees of the clinical study site or any other individuals involved with the conduct of the study, or first degree family members of such individuals (that is, parents, siblings, or children)
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MedImmune LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Gossage, M.D.
Role: STUDY_DIRECTOR
MedImmune LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Encinitas, California, United States
Research Site
Los Angeles, California, United States
Research Site
Colorado Springs, Colorado, United States
Research Site
Wheaton, Maryland, United States
Allergy Associates Research Center
Portland, Oregon, United States
Research Site
Upland, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Attachments tab: MI-CP197 Redacted Protocol\_22\_Jul\_2015
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MI-CP197
Identifier Type: -
Identifier Source: org_study_id